Nurix Therapeutics vs Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical is the larger business, with $673m of revenue in fiscal 2025 against $84.0m for Nurix Therapeutics (8.0 times as much). Nurix Therapeutics grew faster (54.0% against 20.2%). Ultragenyx Pharmaceutical kept more of each dollar of sales as profit: a net margin of -85.4% against -314.9%.
| Latest fiscal year | Nurix TherapeuticsNRIX, 2025 | Ultragenyx PharmaceuticalRARE, 2025 |
|---|---|---|
| Revenue | $84.0m | $673m |
| Revenue growth | 54.0% | 20.2% |
| Net income | −$264m | −$575m |
| Operating margin | -340.2% | -79.5% |
| Net margin | -314.9% | -85.4% |
| Return on equity | -49.6% | — |
| Free cash flow | −$263m | −$472m |
| Cash | $247m | $421m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 317 | 1,371 |
| Market value | $2.81bn | $1.65bn |
| Price vs our value range | — | — |
| Moat score | 11 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 44 sales | 0 buys, 28 sales |